verslaving cocaine addiction drug dependence
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Male, aged 18-60 years; 2) Current DSM-IV diagnosis of cocaine dependence, but recently detoxified and abstinent. 3) Able to provide written informed consent and to comply with all study procedures.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1) Currently dependent on any substance other than cocaine or nicotine; 2) Severe neurological or psychiatric disorders (e.g., depression, psychosis, bipolar illness, dementia, or any diseases that require psychotropic medications); 3) Serious medical illnesses 4) Known hypersensitivity or allergy to rimonabant, or receiving chronic therapy with medication that could interact adversely with one of the medications under study, within 30 days prior to randomization; 5) Drugs known to influence binding to DA2 receptors, including neuroleptics, and methylphenidate 6) Received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment 7) Clinically significant abnormal laboratory values; 8) Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Research assesing the availability of striatal D2 receptors. Craving and impulsivity. Research assesing the respons towards cocaine-associated "cues". Rimonabant may induce an increased availability of striatal D2 receptors. This could subsequently reduce craving to cocaine and/or impulsivity in human cocaine users. | — |
Countries
Netherlands
Outcome results
None listed